News

FDA Approves Daliresp Dosage as First-line Therapy for Severe COPD

AstraZeneca’s Daliresp (roflumilast) is now approved at 250 micrograms (mcg) for the first four weeks followed by 500 mcg thereafter to treat patients with chronic obstructive pulmonary disease (COPD). This approval by the U.S. Food and Drug Administration (FDA) will help reduce the rate of discontinuation previously reported in patients…

Airway Branch Variations Found That May Indicate Risk for COPD

Variations in the anatomy of airway branches may be used as indicators for people at higher risk of developing chronic obstructive pulmonary disease (COPD), a new study found. The team of researchers, funded by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH), discovered…

UK Adds Endobronchial Valves to Standard of Care for Severe Emphysema

The U.K.’s National Institute for Health and Care Excellence (NICE) has updated its guidelines to include endobronchial valves as an appropriate routine treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD). This announcement comes on the heels of positive safety and effectiveness data from multiple…